Why olezarsen data and conference appearances matter for Ionis Pharmaceuticals stock Ionis Pharmaceuticals (IONS) is back in focus after fresh updates on its late stage pipeline, including new Phase 3
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Analysts are heralding bepirovirsen as a potentially strong future growth driver for GSK and its infectious disease portfolio.
The fair value estimate for Ionis Pharmaceuticals has shifted from US$96.73 to US$100.92, a modest reset that puts fresh numbers around the stock. This move comes during an active period of Street res
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into
Pharmaceutical companies have spent years targeting a common blood particle associated with heart-attack risks.
This readout could boost Tryngolza’s standing in its potential rivalry with Arrowhead’s Redemplo in severe hypertriglyceridemia.
View interactive chart, options flow, and AI analysis for IONS on Zorveq Finance.
Open IONS Chart & Analysis →